Johnson & Johnson (NYSE:JNJ) announced today that it has launched the J&J Centers for Global Health Discovery, a global network of research partnerships to address the world’s health challenges.
The first J&J Satellite Center for Global Health Discovery is at the London School of Hygiene & Tropical Medicine. The pharma and medtech giant plans to open additional J&J Centers through 2022.
Each Satellite Center will focus on entrenched and emerging health threats that are pressing and have a high unmet need. Think tuberculosis (TB), dengue fever, flavivirus, the novel coronavirus and antimicrobial resistance (AMR).
“COVID-19 has shown us that investments in early-stage research, such as novel vaccine technologies, are critical to accelerate our fight against pandemic threats. The J&J Centers for Global Health Discovery are the latest chapter in our efforts to turn science into solutions for diseases that continue to threaten communities worldwide,” said Dr. Paul Stoffels, J&J executive committee vice chair and chief scientific officer.
“This collaborative approach to science is essential to accelerate innovations from the lab to the last mile, address the global health inequities laid bare by the COVID-19 pandemic and improve our health security,” Stoffels said in a news release.
Filed Under: Drug Discovery, Drug Discovery and Development, Infectious Disease, RD
